乙型肝炎病毒
医学
肝细胞癌
清脆的
中止
乙型肝炎
效应器
病毒学
治疗方式
免疫学
重症监护医学
病毒
生物
癌症研究
内科学
基因
生物化学
作者
Raymond F. Schinazi,Maryam Ehteshami,Leda Bassit,Tarik Asselah
摘要
Tremendous progress has been made over the last 2 decades to discover and develop approaches to control hepatitis B virus (HBV) infections and to prevent the development of hepatocellular carcinoma using various interferons and small molecules as antiviral agents. However, none of these agents have significant impact on eliminating HBV from infected cells. Currently the emphasis is on silencing or eliminating cccDNA, which could lead to a cure for HBV. Various approaches are being developed including the development of capsid effectors, CRISPR/Cas9, TALENS, siRNA, entry and secretion inhibitors, as well as immunological approaches. It is very likely that a combination of these modalities will need to be employed to successfully eliminate HBV or prevent virus rebound on discontinuation of therapy. In the next 5 years clinical data will emerge which will provide insight on the safety and feasibility of these approaches and if they can be applied to eradicate HBV infections globally. In this review, we summarize current treatments and we highlight and examine recent therapeutic strategies that are currently being evaluated at the preclinical and clinical stage.
科研通智能强力驱动
Strongly Powered by AbleSci AI